Table 2.
Univariate linear regression analysis of subfoveal choroidal thickness measurements by enhanced depth imaging-optical coherence tomography
|
|
β, 95%CI
|
P value
|
| Male vs female | 31.08 (9.81 to 52.36) | 0.0046 |
| Age, per 1-year increase | -2.44 (-3.46 to -1.42) | < 0.0001 |
| Education level | ||
| Junior high school or below | Reference | |
| Senior high school | -19.95 (-48.87 to 8.97) | 0.1778 |
| College or above | 2.39 (-25.48 to 30.26) | 0.8666 |
| SBP, per 1 mmHg increase | 0.42 (-0.11 to 0.95) | 0.1222 |
| DBP, per 1 mmHg increase | 1.27 (0.26 to 2.27) | 0.0141 |
| Height, per 1 cm increase | 1.74 (0.41 to 3.08) | 0.0111 |
| Weight, per 1 cm increase | 1.17 (0.17 to 2.17) | 0.0234 |
| BMI, per 1 kg/m2 increase | 1.96 (-1.63 to 5.55) | 0.2865 |
| Duration of diabetes, per 1-year increase | -0.40 (-1.99 to 1.20) | 0.6269 |
| Hypertension vs absent | -2.97 (-24.42 to 18.48) | 0.7862 |
| Diabetic nephropathy history vs absent | 40.23 (13.83 to 66.64) | 0.0031 |
| Stroke history vs absent | 2.07 (-46.41 to 50.55) | 0.9333 |
| Anemia vs absent | 12.80 (-10.31 to 35.91) | 0.2788 |
| Heart disease vs absent | -19.42 (-67.84 to 28.99) | 0.4325 |
| PRP | ||
| None | Reference | |
| Partial | 4.02 (-24.99 to 33.03) | 0.7861 |
| Whole | 31.00 (7.32 to 54.69) | 0.0109 |
| Anti-VEGF therapy vs absent | 30.55 (6.24 to 54.86) | 0.0145 |
| Insulin vs absent | 23.81 (2.63 to 44.99) | 0.0286 |
| Oral glucose-lowering drugs vs absent | -28.96 (-53.31 to -4.62) | 0.0205 |
| Calcium antagonists vs absent | 40.49 (14.86 to 66.13) | 0.0022 |
| Visual acuity, per 1 LogMAR increase | -12.24 (-32.49 to 8.01) | 0.2374 |
| IOP, per 1 mmHg increase | 2.27 (-0.32 to 4.86) | 0.0876 |
| Fasting blood glucose, per 1 mmol/L increase | -2.34 (-6.06 to 1.39) | 0.2201 |
| Serum urea nitrogen, per 1 mmol/L increase | 1.63 (-0.81 to 4.06) | 0.1910 |
| Serum creatinine, per 1 μmol/L increase | 0.08 (0.02 to 0.14) | 0.0092 |
| eGFR, per 1 mL/minutes × 1.73m2 increase | -0.15 (-0.50 to 0.20) | 0.3938 |
| Uric acid, per 1 mmol/L | -0.01 (-0.14 to 0.11) | 0.8322 |
| Triglyceride, per 1 mmol/L increase | -3.01 (-24.36 to 18.34) | 0.7828 |
| Total cholesterol, per 1 mmol/L increase | -16.08 (-29.25 to -2.91) | 0.0181 |
| HDL-C, per 1 mmol/L increase | -42.66 (-81.44 to -3.89) | 0.0329 |
| LDL-C, per 1 mmol/L increase | -15.27 (-30.72 to 0.17) | 0.0548 |
| HbA1c, per 1 % increase | -5.36 (-16.77 to 6.04) | 0.3590 |
| CMT, per 1 μm increase | 0.02 (-0.06 to 0.11) | 0.5839 |
| Ocular axial length, per 1 mm increase | -18.57 (-34.96 to -2.18) | 0.0282 |
CI: Confidence interval; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; HbA1c: Hemoglobin A1c; logMAR: Logarithmic minimum resolution angle; IOP: Intraocular pressure; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; eGFR: Estimated glomerular filtration rate; CMT: Central macular thickness; SFCT: Subfoveal choroidal thickness; VEGF: Vascular endothelial growth factor; PRP: Pan-retinal photocoagulation.